Protagonist Therapeutics PTGX Business Segments — Employee Expense Benefit Related To Development

Similar metrics at other companies

INSMReportable Segment — R&D compensation and benefit-related expenses

$72.14M+34.7%

ACLSSingle Reportable — Research And Development Expense

$28.52M+5.1%

EXELReportable Segment — Development

$135.72M-11.4%

RYTMSingle reportable segment — Preclinical, clinical and development expense

$18.51M-7.3%

SRRKSingle Reportable — Labor And Related Expense

$37.53M+63.6%

MIRMReportable Segment — Research and development expenses (excluding stock-based compensation)

$73.72M+106%

Questions, answered.

What is Protagonist Therapeutics's business segments — employee expense benefit related to development?

Protagonist Therapeutics (PTGX) reported business segments — employee expense benefit related to development of $5.95M in Q1 2026.

How has Protagonist Therapeutics's business segments — employee expense benefit related to development changed year-over-year?

Protagonist Therapeutics's business segments — employee expense benefit related to development increased by 8.5% year-over-year, from $5.49M to $5.95M.

What is the long-term trend for Protagonist Therapeutics's business segments — employee expense benefit related to development?

Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — employee expense benefit related to development has grown at a 3.5% compound annual growth rate (CAGR), from $19.28M to $21.39M.

What does business segments — employee expense benefit related to development mean?

This captures the cash-based compensation and benefits for staff focused on clinical development, including clinical operations, regulatory affairs, and medical affairs. It serves as a proxy for the company's investment in the human resources necessary to execute clinical trials and navigate regulatory pathways. This is a key indicator of the company's commitment to advancing its pipeline toward market approval.